Incyte Corp Company Profile

What is the competitive landscape for INCYTE CORP

INCYTE CORP has four approved drugs.

There are forty-one US patents protecting INCYTE CORP drugs.

Summary for Incyte Corp

US Patents:	41
Tradenames:	4
Ingredients:	2
NDAs:	4
Patent Litigation for Incyte Corp:	See patent lawsuits for Incyte Corp
PTAB Cases with Incyte Corp as petitioner:	See PTAB cases with Incyte Corp as petitioner

Drugs and US Patents for Incyte Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-002	Apr 17, 2020		RX	Yes	No
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-002	May 1, 2026		RX	Yes	No	11,576,865*PED				Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	9,079,912*PED				Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-003	May 1, 2026		RX	Yes	No	11,337,927*PED				Y
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-002	Apr 17, 2020		RX	Yes	No
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes	12,564,593		Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-005	Nov 16, 2011		RX	Yes	Yes	10,016,429*PED				Y

Paragraph IV (Patent) Challenges for INCYTE CORP drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg		2015-12-17

International Patents for Incyte Corp Drugs

Country	Patent Number	Estimated Expiration
Lithuania	3184526
San Marino	T201600172
Slovenia	3495367
Lithuania	2919766
Cyprus	1118744
Montenegro	00960
Japan	2019178156

Supplementary Protection Certificates for Incyte Corp Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2861595	21C1041	France		PRODUCT NAME: PEMIGATINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1535 20210329
1966202	145 1-2013	Slovakia		FORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US;
2861595	122021000054	Germany		PREVIOUS REPRESENTATIVE: UEXKUELL & STOLBERG PARTNERSCHAFT VON PATENT- UND RECHTSANWAELTEN MBB, 22607 HAMBURG, DE; PRODUCT NAME: PEMIGATINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; AUTHORISATION NO/DATE: EU/1/21/1535 20210326
1966202	300574	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120828
2861595	C02861595/01	Switzerland		PRODUCT NAME: PEMIGATINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68143 13.07.2021
2861595	132021000000140	Italy		PRODUCT NAME: PEMIGATINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(PEMAZYRE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/21/1535, 20210329
1966202	2013/004	Ireland		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THREOF; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Incyte Corp